|
Nutrition Journal 2012
MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adultsKeywords: Folic acid supplementation, MTHFR C677T polymorphism, MTR A2756G polymorphism, Homocysteine-lowering efficacy Abstract: A total of 480 subjects with mild or moderate essential hypertension were randomly assigned to three treatment groups: 1) enalapril only (10 mg, control group); 2) enalapril-FA tablet [10:0.4 mg (10 mg enalapril combined with 0.4 mg of FA), low FA group]; and 3) enalapril-FA tablet (10:0.8 mg, high FA group), once daily for 8 weeks.After 4 or 8 weeks of treatment, homocysteine concentrations were reduced across all genotypes and FA dosage groups, except in subjects with MTR 2756AG /GG genotype in the low FA group at week 4. However, compared to subjects with MTHFR 677CC genotype, homocysteine concentrations remained higher in subjects with CT or TT genotype in the low FA group (P < 0.05 for either of these genotypes) and TT genotype in the high FA group (P < 0.05). Furthermore, subjects with TT genotype showed a greater homocysteine-lowering response than did subjects with CC genotype in the high FA group (mean percent reduction of homocysteine at week 8: CC 10.8% vs. TT: 22.0%, P = 0.005), but not in the low FA group (CC 9.9% vs. TT 11.2%, P = 0.989).This study demonstrated that MTHFR C677T polymorphism can not only affect homocysteine concentration at baseline and post-FA treatment, but also can modify therapeutic responses to various dosages of FA supplementation.Traditional risk factors are estimated to account for only part of cardiovascular disease (CVD) risk [1]. Non-traditional risk factors such as increased homocysteine concentrations are believed to be causally related to CVD [2]. The interactive effect between hypertension and hyperhomocysteinemia on the risk of CVD has received great attention [3]. Our previous meta-analysis [4] suggested that folic acid (FA) supplementation could significantly reduce the risk of stroke by 18% [Relative Risk (RR):0.82, 95% Confidence Interval (CI): 0.68-1.00; P = 0.045), and an even greater beneficial effect was seen in those trials with no or partial FA fortification (RR: 0.75, 95%CI: 0.62-0.91; P = 0.003). Furthermore,
|